Chronic Hepatitis B Infection
15
3
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
27%
4 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (15)
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum
Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B
Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
Study on Gut Microbiota in Chronic HBV Infected Patients
Quality of Life and Health Utility of Patients With CHB Infections
The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy
The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy
The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy
The Changes of Cytokines During Antiviral Therapy
The Changes of Treg Cells Frequency and Function During Antiviral Therapy
The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Antiviral Therapy